Copyright
©The Author(s) 2022.
World J Gastrointest Pathophysiol. May 22, 2022; 13(3): 96-106
Published online May 22, 2022. doi: 10.4291/wjgp.v13.i3.96
Published online May 22, 2022. doi: 10.4291/wjgp.v13.i3.96
Table 1 Characteristics of patients with nonalcoholic fatty liver disease
Patients (n) | 191 |
Age (years old) | 62 (20-90) |
Men (%) | 81 (42.4) |
diabetes (%) | 75 (39.3) |
HCC | 17 |
EGV | 16 |
Both HCC and EGV | 9 |
AST (U/L) | 36 (13-208) |
ALT (U/L) | 40 (10-214) |
Platelet count (×109/L) | 207 (45-445) |
Table 2 Sensitivity, specificity, positive predictive value, and negative predictive value of each score and marker (L vs I-H)
FIB-4 | FAST | Agile 3+ | Agile 4 | LSM | M2BPGi | |||||||
Risk | L | I-H | L | I-H | L | I-H | L | I-H | L | I-H | L | I-H |
n | 71 | 120 | 87 | 104 | 96 | 95 | 131 | 60 | 73 | 118 | 102 | 89 |
HCC | 0 | 26 | 10 | 16 | 0 | 26 | 7 | 19 | 4 | 22 | 5 | 21 |
P value | < 0.01 | 0.44 | < 0.01 | < 0.01 | < 0.01 | < 0.01 | ||||||
Sensitivity | 1 | 0.62 | 1 | 0.73 | 0.85 | 0.81 | ||||||
Specificity | 0.43 | 0.53 | 0.58 | 0.79 | 0.44 | 0.62 | ||||||
PPV | 0.22 | 0.17 | 0.27 | 0.36 | 0.19 | 0.25 | ||||||
NPV | 1 | 0.90 | 1 | 0.95 | 0.95 | 0.95 | ||||||
EGV | 0 | 25 | 6 | 19 | 0 | 25 | 1 | 24 | 0 | 25 | 1 | 24 |
P value | < 0.01 | 0.02 | < 0.01 | < 0.01 | < 0.01 | < 0.01 | ||||||
Sensitivity | 1 | 0.76 | 1 | 0.96 | 1 | 0.96 | ||||||
Specificity | 0.43 | 0.52 | 0.58 | 0.79 | 0.44 | 0.61 | ||||||
PPV | 0.21 | 0.19 | 0.26 | 0.41 | 0.21 | 0.27 | ||||||
NPV | 1 | 0.94 | 1 | 0.99 | 1 | 0.99 |
Table 3 Sensitivity, specificity, positive predictive value, and negative predictive value of each score and marker (L-I vs H)
FIB-4 | FAST | Agile 3+ | Agile 4 | LSM | M2BPGi | |||||||
Risk | L-I | H | L-I | H | L-I | H | L-I | H | L-I | H | L-I | H |
n | 122 | 69 | 146 | 45 | 111 | 80 | 148 | 43 | 136 | 55 | 148 | 43 |
HCC | 3 | 23 | 18 | 8 | 0 | 26 | 12 | 14 | 10 | 16 | 11 | 15 |
P value | < 0.01 | 0.35 | < 0.01 | < 0.01 | < 0.01 | < 0.01 | ||||||
Sensitivity | 0.89 | 0.31 | 1 | 0.54 | 0.62 | 0.58 | ||||||
Specificity | 0.74 | 0.89 | 0.67 | 0.90 | 0.82 | 0.90 | ||||||
PPV | 0.35 | 0.30 | 0.33 | 0.45 | 0.36 | 0.47 | ||||||
NPV | 0.98 | 0.89 | 1 | 0.93 | 0.93 | 0.93 | ||||||
EGV | 2 | 23 | 14 | 11 | 0 | 25 | 2 | 23 | 3 | 22 | 4 | 21 |
P value | < 0.01 | 0.01 | < 0.01 | < 0.01 | < 0.01 | < 0.01 | ||||||
Sensitivity | 0.92 | 0.44 | 1 | 0.92 | 0.88 | 0.84 | ||||||
Specificity | 0.74 | 0.88 | 0.67 | 0.89 | 0.82 | 0.89 | ||||||
PPV | 0.34 | 0.36 | 0.31 | 0.56 | 0.42 | 0.54 | ||||||
NPV | 0.98 | 0.91 | 1 | 0.99 | 0.98 | 0.97 |
Table 4 The prevalence of esophagogastric varices in Baveno VI criteria and its derivatives
Baveno VI | Exp. Baveno VI | New NASH C.C | ||||
LSM | platelet | LSM | platelet | LSM | platelet | |
< 20 | 150 < | < 25 | 110 < | < 30 | 110 < | |
EGV/rule in (n) | 12/26 | 8/13 | 6/9 | |||
EGV/rule out (n) | 13/165 | 17/178 | 19/182 |
- Citation: Miura K, Maeda H, Morimoto N, Watanabe S, Tsukui M, Takaoka Y, Nomoto H, Goka R, Kotani K, Yamamoto H. Utility of FibroScan-based scoring systems to narrow the risk group of nonalcoholic fatty liver disease with comorbidities. World J Gastrointest Pathophysiol 2022; 13(3): 96-106
- URL: https://www.wjgnet.com/2150-5330/full/v13/i3/96.htm
- DOI: https://dx.doi.org/10.4291/wjgp.v13.i3.96